Literature DB >> 12160950

Inhibiting mitochondrial permeability transition pore opening: a new paradigm for myocardial preconditioning?

Derek J Hausenloy1, Helen L Maddock, Gary F Baxter, Derek M Yellon.   

Abstract

OBJECTIVE: We propose that ischemic preconditioning (IPC) and mitochondrial K(ATP) channel activation protect the myocardium by inhibiting mitochondrial permeability transition pore (MPTP) opening at reperfusion.
METHODS: Isolated rat hearts were subjected to 35 min ischemia/120 min reperfusion and assigned to the following groups: (1) control; (2) IPC of 2x5 min each of preceding global ischemia; (3,4,5) 0.2 micromol/l cyclosporin A (CsA, which inhibits MPTP opening), 5 micromol/l FK506 (which inhibits the phosphatase calcineurin without inhibiting MPTP opening), or 20 micromol/l atractyloside (Atr, a MPTP opener) given at reperfusion; (6,7) pre-treatment with 30 micromol/l diazoxide (Diaz, a mitochondrial K(ATP) channel opener) or 200 nmol/l 2 chloro-N(6)-cyclopentyl-adenosine (CCPA, an adenosine A1 receptor agonist); (8) IPC+Atr; (9) Diaz+Atr; (10) CCPA+Atr. The effect of mitochondrial K(ATP) channel activation on calcium-induced MPTP opening in isolated calcein-loaded mitochondria was also assessed.
RESULTS: IPC, CsA when given at reperfusion, and pre-treatment with diazoxide or CCPA all limited infarct size (19.9+/-2.6% in IPC; 24.6+/-1.9% in CsA, 18.0+/-1.7% in Diaz, 20.4+/-3.3% in CCPA vs. 44.7+/-2.0% in control, P<0.0001). Opening the MPTP with atractyloside at reperfusion abolished this cardio-protective effect (47.7+/-1.8% in IPC+Atr, 42.3+/-3.2% in Diaz+Atr, 51.2+/-1.6% in CCPA+Atr). Atractyloside and FK506, given at reperfusion, did not influence infarct size (45.7+/-2.1% in Atr and 43.1+/-3.6% in FK506 vs. 44.7+/-2.0% in control, P=NS). Diazoxide (30 micromol/l) was shown to reduce calcium-induced MPTP opening by 52.5+/-8.0% in calcein-loaded mitochondria. 5-Hydroxydecanoic acid (100 micromol/l) was able to abolish the cardio-protective effects of both diazoxide and IPC.
CONCLUSION: One interpretation of these data is that IPC and mitochondrial K(ATP) channel activation may protect the myocardium by inhibiting MPTP opening at reperfusion.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12160950     DOI: 10.1016/s0008-6363(02)00455-8

Source DB:  PubMed          Journal:  Cardiovasc Res        ISSN: 0008-6363            Impact factor:   10.787


  135 in total

1.  Conditioned medium from hypoxic cells protects cardiomyocytes against ischemia.

Authors:  B Chanyshev; A Shainberg; A Isak; Y Chepurko; E Porat; E Hochhauser
Journal:  Mol Cell Biochem       Date:  2011-12-08       Impact factor: 3.396

Review 2.  Mitochondria are sources of metabolic sink and arrhythmias.

Authors:  Fadi G Akar; Brian O'Rourke
Journal:  Pharmacol Ther       Date:  2011-04-14       Impact factor: 12.310

Review 3.  Signaling and cellular mechanisms in cardiac protection by ischemic and pharmacological preconditioning.

Authors:  Michael Zaugg; Marcus C Schaub
Journal:  J Muscle Res Cell Motil       Date:  2003       Impact factor: 2.698

4.  Ischaemic preconditioning inhibits opening of mitochondrial permeability transition pores in the reperfused rat heart.

Authors:  Sabzali A Javadov; Samantha Clarke; Manika Das; Elinor J Griffiths; Kelvin H H Lim; Andrew P Halestrap
Journal:  J Physiol       Date:  2003-04-11       Impact factor: 5.182

Review 5.  Mitochondrial morphology and cardiovascular disease.

Authors:  Sang-Bing Ong; Derek J Hausenloy
Journal:  Cardiovasc Res       Date:  2010-07-14       Impact factor: 10.787

6.  Ascorbic acid mitigates the myocardial injury after cardiac arrest and electrical shock.

Authors:  Min-Shan Tsai; Chien-Hua Huang; Chia-Ying Tsai; Huei-Wen Chen; Hsin-Chen Lee; Hsaio-Ju Cheng; Chiung-Yuan Hsu; Tzung-Dau Wang; Wei-Tien Chang; Wen-Jone Chen
Journal:  Intensive Care Med       Date:  2011-09-28       Impact factor: 17.440

Review 7.  Mechanism of cardioprotection by early ischemic preconditioning.

Authors:  Xiulan Yang; Michael V Cohen; James M Downey
Journal:  Cardiovasc Drugs Ther       Date:  2010-06       Impact factor: 3.727

Review 8.  Functional O-GlcNAc modifications: implications in molecular regulation and pathophysiology.

Authors:  Krithika Vaidyanathan; Sean Durning; Lance Wells
Journal:  Crit Rev Biochem Mol Biol       Date:  2014-02-14       Impact factor: 8.250

Review 9.  Potential therapeutic benefits of strategies directed to mitochondria.

Authors:  Amadou K S Camara; Edward J Lesnefsky; David F Stowe
Journal:  Antioxid Redox Signal       Date:  2010-08-01       Impact factor: 8.401

10.  Exogenous zinc protects cardiac cells from reperfusion injury by targeting mitochondrial permeability transition pore through inactivation of glycogen synthase kinase-3beta.

Authors:  Guillaume Chanoit; SungRyul Lee; Jinkun Xi; Min Zhu; Rachel A McIntosh; Robert A Mueller; Edward A Norfleet; Zhelong Xu
Journal:  Am J Physiol Heart Circ Physiol       Date:  2008-07-25       Impact factor: 4.733

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.